About chornixadm

This author has not yet filled in any details.
So far chornixadm has created 66 blog entries.

Absolute Quantification of Graft-Derived Cell-Free DNA as a Marker of Rejection and Graft Injury in Kidney Transplantation – Results from a Prospective Observational Trial

By |2018-08-24T09:33:54+00:00August 1st, 2018|Peer-reviewed medical publications|0 Comments

Early detection of cancer – why is it important?

The number of people diagnosed with tumors, especially malignant ones, is constantly increasing. There is also a rise in mortality rate due to delayed diagnosis and inappropriate treatment. Therefore, proper cancer diagnosis is very important. Early detection of a tumor makes it more probable that the patient will, finally, beat the cancer and recover. However, [...]

By |2019-03-21T09:37:56+00:00July 6th, 2017|Chronix news|0 Comments

It was the 5th year that Chronix Biomedical has been present at ASCO Annual Meeting in Chicago

This was the busiest ASCO conference yet for Chronix Biomedical. Chronix booth was visited by clinical trial oncologists, international cancer research...

By |2019-03-21T09:37:56+00:00June 22nd, 2017|Chronix news, Events|0 Comments

Chronix Biomedical reports positive interim pancreatic cancer data

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.

By |2019-03-21T09:37:57+00:00June 14th, 2017|Chronix news|0 Comments

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO

Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion. The study enrolled 54 patients undergoing surgery for this cancer type and evaluated the Chronix test as a predictor of time to progression in comparison with the current method based on the degree of tumour invasion of lymph nodes (pN status).

By |2019-03-21T09:37:57+00:00June 5th, 2017|Chronix news|0 Comments

Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO. Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion.

By |2018-08-24T09:33:55+00:00June 5th, 2017|Peer-reviewed medical publications|0 Comments